Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
Autor: | Clayton A. Dehn, Sabina Paglialunga |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Fatty acid indexes Clinical chemistry Stable label isotope Endocrinology Diabetes and Metabolism Clinical Biochemistry Disease Clinical nutrition Review Indirect calorimetry Fructose Biology Bioinformatics digestive system 03 medical and health sciences 0302 clinical medicine Endocrinology Non-alcoholic Fatty Liver Disease MIDA medicine Humans Biochemistry medical chemistry.chemical_classification Lipogenesis Biochemistry (medical) Fatty liver Fatty Acids Fatty acid nutritional and metabolic diseases medicine.disease digestive system diseases Diet 030104 developmental biology Clinical research chemistry Liver Isotope Labeling 030211 gastroenterology & hepatology Lipidology |
Zdroj: | Lipids in Health and Disease |
ISSN: | 1476-511X |
Popis: | Non-alcoholic fatty liver disease (NAFLD) is heralded as the next big global epidemic. Hepatic de novo lipogenesis (DNL), the synthesis of new fatty acids from non-lipid sources, is thought to play a pivotal role in the development of NAFLD. While there is currently no NAFLD-specific therapeutic agent available, pharmaceutical drugs aimed at reducing hepatic fat accretion may prove to be a powerful ally in the treatment and management of this disease. With a focus on NAFLD, the present review summarizes current techniques examining DNL from a clinical perspective, and describes the merits and limitations of three commonly used assays; stable-label isotope tracer studies, fatty acid indexes and indirect calorimetry as non-invasive measures of hepatic DNL. Finally, the application of DNL assessments in the pharmacological and nutraceutical treatment of NAFLD/NASH is summarized. In a clinical research setting, measures of DNL are an important marker in the development of anti-NAFLD treatments. |
Databáze: | OpenAIRE |
Externí odkaz: |